Skip to content

cms.bioaccessla.com

Australia vs Latin America for Clinical Trials: A 2026 Guide for MedTech and Biopharma Sponsors
From first-in-human to US pivotal | bioaccess®
Post-trial access (PTA) in Latin America: operator hub | bioaccess®
Sample Budget: A Typical First-in-Human Medical Device Trial in Latin America
US Execution: US-Anchored Regulatory Strategy + Clinical Site | bioaccess®

Clinical trial insurance for medical device studies in Latin America

Written by

Julio Martinez-Clark

in

Clinical Research, First-in-Human

This guide has been merged into our updated hub, Clinical Trial Liability Insurance in Latin America: Requirements by Country, which sets out each country’s rule with links to the primary legal text (verified 29 October 2026).

←El Salvador first-in-human cost and timeline vs the United States

Investigator-Initiated Studies: What Sponsors Need to Know→

More posts

Latam Research Associates (Panama) vs a First-in-Human Device CRO (bioaccess®)

November 4, 2026
Changing your distributor or importer on a COFEPRIS device registration: Modality A vs. B after the 2025 simplification, and what to do if the application is still pending

November 4, 2026
Importing investigational devices into Colombia for a first-in-human study: INVIMA approval, VUCE and the mistakes that delay start-up

November 3, 2026
Visionware Clinical Sydney vs a Latin America First-in-Human Device CRO (bioaccess®)

November 2, 2026

cms.bioaccessla.com

Blog
About
FAQs
Authors

Events
Shop
Patterns
Themes

Twenty Twenty-Five

Designed with WordPress